Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07707388

Effect of Theravex Tissue Care on Implant Stability

The aim of this randomized clinical trial is to evaluate the clinical and radiographic outcomes of using Bone Bioactive Liquid (Theravex) compared to Xenograft and a combination therapy (Theravex + Xenograft) during immediate implant placement in the esthetic zone.

When a tooth is extracted and replaced immediately with a dental implant, bone grafting is often necessary to fill the gap (jumping distance) between the implant and the surrounding bone socket to support tissue healing and maintain facial contour.

Participants requiring immediate implant placement will be randomly assigned into three groups:

Group 1: Immediate implant placement using Bone Bioactive Liquid (Theravex).

Group 2: Immediate implant placement using Xenograft alone.

Group 3: Immediate implant placement using Combination Therapy (Theravex + Xenograft).

The primary outcomes will evaluate implant stability, bone dimensional changes, and soft tissue response around the implants over the follow-up period.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Faculty of Dentistry - Ain Shams University

Cairo, 11566, Egypt

About this study

Background and Rationale:

Immediate implant placement in extraction sockets has become a widely accepted clinical protocol due to reduced treatment time, fewer surgical interventions, and preservation of surrounding hard and soft tissue architecture. However, post-extraction bone remodeling often leads to horizontal and vertical dimensional changes, particularly at the buccal bone plate. To counteract these changes and ensure long-term stability and esthetics, grafting the peri-implant defect (jumping space) is commonly performed.

Study Objectives:

The main objective of this study is to compare the efficacy of Bone Bioactive Liquid (Theravex), Xenograft material, and their combination in enhancing early osseointegration, maintaining bone dimensions, and supporting peri-implant tissue health during immediate implant placement.

Methodology:

Following thorough clinical and radiographic evaluations (including CBCT scans), eligible patients requiring single-tooth extraction and immediate implant placement in the esthetic zone will be enrolled. Surgical procedures will follow standard aseptic protocols. After atraumatic tooth extraction and precise osteotomy preparation, dental implants will be placed according to standard manufacturer guidelines.

Patients will be randomly allocated into three intervention arms:

Group A: Receives Bone Bioactive Liquid (Theravex) in the peri-implant gap.

Group B: Receives Xenograft material alone.

Group C: Receives Combination Therapy (Theravex combined with Xenograft).

Follow-up & Assessments:

Baseline clinical parameters (e.g., primary stability via ISQ/RFA) and initial CBCT measurements will be recorded. Patients will be evaluated postoperatively at standardized time intervals to assess secondary stability, soft tissue healing, peri-implant mucosal parameters, and marginal bone level changes using standardized radiographic imaging.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient requires extraction of a single failing or non-restorable maxillary anterior tooth or premolar.
  • Presence of an intact buccal bone plate (Socket Type I) with a horizontal peri-implant jumping gap ≥ 2 mm.
  • The implant can be placed in an ideal 3-D position with an intraoperative primary stability target of ≥ 35 Ncm.
  • Patient is in good general health with no systemic contraindications to implant surgery.
  • Patient is cooperative and available for the entire 6-month follow-up period

Exclusion criteria

  • Pregnant and lactating females.
  • Heavy smokers (smoking ≥ 10 cigarettes per day).
  • Patients with poor oral hygiene.
  • Patients with occlusal or malalignment problems.
  • Patients with parafunctional habits (e.g., bruxism).

Treatment and study plan

Bone Bioactive Liquid

Device

A bone bioactive liquid (Theravex) applied directly into the jumping gap and on implant surface immediately following implant placement to stimulate early bone healing and osseointegration.

Other names: Theravex

Bovine-derived Xenograft

Device

Bovine derived- xenograft will be packed into the jumping gap to maintain volume and provide an osteoconductive scaffold for bone formation.

Immediate Implant Placement

Procedure

Surgical placement of the dental implant into the fresh extraction socket immediately following tooth extraction, according to standard surgical protocols.

Primary outcomes

  1. Implant Stability Quotient (ISQ)

    Time frame: Baseline (during surgery), 4 weeks, 3 months, and 6 months post-operatively.

    Implant stability will be measured using Resonance Frequency Analysis (RFA) to record the Implant Stability Quotient (ISQ) values.

Secondary outcomes

  1. Bone Density

    Time frame: 6 months post-operatively.

    Radiographic evaluation of peri-implant bone density within the jumping gap utilizing standardized low-dose Cone-Beam Computed Tomography (CBCT) scans.

  2. Mid-facial Gingival Margin Level

    Time frame: Baseline (immediately post-operative), 3 months, and 6 months post-operatively.

    Assessment of mid-facial tissue recession and soft-tissue alterations evaluated using superimposed standardized intra-oral digital scans with predefined reference points.

  3. Oral Health-Related Quality of Life (OHIP-14)

    Time frame: Pre-operatively (baseline), 7 days, 3 months, and 6 months post-operatively.

    Patient-reported oral health-related quality of life will be assessed using the Oral Health Impact Profile-14 (OHIP-14) questionnaire. The scale consists of 14 items, with each item scored on a 5-point Likert scale from 0 (never) to 4 (very often). The total score is calculated by summing the scores of all items, ranging from a minimum value of 0 to a maximum value of 56. Higher scores represent a worse outcome (greater negative impact on oral health-related quality of life), while lower scores represent a better outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Abdallah A Aref, M.D.S

CONTACT

[email protected]

00201111711467

Susan M Sarhan

CONTACT

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

Effect of Theravex Tissue Care on Implant Stability in Immediate Implant Placement: A Randomized Controlled Clinical Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 16, 2026
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.